13F Portfolios

Vestal Point Capital, LP 13F: Portfolio & Holdings

Vestal Point Capital, LP (SEC CIK 0001974915) reported 68 positions with a combined market value of $4.3 billion in its most recent SEC Form 13F-HR filing (as of Q2 2026). The New York-based hedge fund has a Healthcare sector tilt, which represents 96.8% of its exposure.

Its largest holdings are Biomarin Pharmaceutical INC (BMRN) at 8.1%, Neurocrine Biosciences INC (NBIX) at 7.4%, and Abivax SA (ABVX) at 7.3%.

The largest position reduction was Revolution Medicines INC (RVMD) (-4.5% of portfolio weight). See the fund’s full Q2 2026 buys, sells, and portfolio changes →

Based on published SEC 13F filings, Vestal Point Capital's closest peer funds by portfolio overlap are Darwin Global Management, Ltd. (81.6%), Investor Ab (67.9%), and Avoro Capital Advisors LLC (55.5%).

13F AUM
$4.3B
Equity Positions
68
Top-10 Concentration
50.3%
Largest Sector · 96.8%
Healthcare
Longest-Held Position · 11 qtrs
IMTX
Median Holding Period
3 Qtrs

What are Vestal Point Capital’s largest 13F holdings as of Q2 2026?

Largest 13F positions disclosed by Vestal Point Capital, ranked by portfolio weight. Full multi-quarter history and the broader institutional holder base for each ticker linked per row.

Top 10 disclosed equity positions for Vestal Point Capital in Q2 2026, ranked by portfolio weight. Share count and market value sourced from SEC Form 13F-HR filings.
# Issuer Ticker Sector Weight Position Value Detail
1 BIOMARIN PHARMACEUTICAL INC BMRN Healthcare 8.1% $344.8M Position History All Holders
2 NEUROCRINE BIOSCIENCES INC NBIX Healthcare 7.4% $316.8M Position History All Holders
3 ABIVAX SA ABVX Healthcare 7.3% $313.1M Position History All Holders
4 UNITED THERAPEUTICS CORP DEL UTHR Healthcare 5.5% $235.7M Position History All Holders
5 ENLIVEN THERAPEUTICS INC ELVN Healthcare 4.7% $203.0M Position History All Holders
6 NURIX THERAPEUTICS INC NRIX Healthcare 4.6% $195.3M Position History All Holders
7 BICARA THERAPEUTICS INC BCAX Healthcare 3.6% $155.9M Position History All Holders
8 TAYSHA GENE THERAPIES INC TSHA Healthcare 3.1% $132.2M Position History All Holders
9 ARROWHEAD PHARMACEUTICALS IN ARWR Healthcare 3.0% $128.4M Position History All Holders
10 ABBOTT LABORATORIES NEW ABT Healthcare 3.0% $127.0M Position History All Holders

View Vestal Point Capital's Q2 2026 portfolio changes and trading report →

Latest

Portfolio composition

Sectors, concentrations, and a tap-through treemap of every position in the fund's latest 13F.

Allocation by stock68 positions · click any tile for institutional holders
Allocation by sector2 sectors · same palette as the stock tiles

Holding period analytics

Distribution of holding periods for all 218 stocks the fund has ever held (up to selected quarter):

Which Funds Hold a Similar Portfolio to Vestal Point Capital?

Ranked by percentage of the peer fund's 13F equity portfolio that overlaps with Vestal Point Capital's positions in Q2 2026.

Funds with the most portfolio overlap with Vestal Point Capital in Q2 2026, ranked by overlap percentage
# Fund Shared Positions Overlap %
1 Darwin Global Management, Ltd. 3 81.6%
2 Investor Ab 2 67.9%
3 Avoro Capital Advisors LLC 11 55.5%
4 Jones Hill Capital LP 9 47.4%
5 Trails Edge Capital Partners, LP 10 39.6%
6 Caligan Partners LP 6 36.2%
7 Paradigm Biocapital Advisors LP 5 30.6%
8 Saturn V Capital Management LP 8 29.8%
9 Tri Locum Partners LP 7 28.5%
10 Fairmount Funds Management LLC 4 28.4%

How Has Vestal Point Capital's AUM Changed Over Time?

Quarterly 13F-reported AUM for Vestal Point Capital, derived from aggregate reported position market values disclosed to the U.S. SEC.

Methodology & FAQ

How We Track Vestal Point Capital Holdings

Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).

  • Who must file: This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
  • What is included: By regulation, 13F filings include long positions in U.S. exchange-listed stocks, ETFs, shares of closed-end investment companies, and convertible debt, as defined in the SEC's official Section 13(f) securities list . For listed options (calls/puts) the reported value is based on the notional value.
  • Metric definition: “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to a specific position on the reporting date.
  • How to use this data: Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
What does Vestal Point Capital's 13F filing disclose about their portfolio?

A Form 13F-HR filed by Vestal Point Capital with the U.S. SEC discloses all long positions in Section 13(f) securities (U.S.-listed equities, ETFs, closed-end funds, and listed put/call options) held at quarter-end with a market value of at least $200,000 or 10,000 or more shares. Pactolio aggregates these filings to surface the manager’s reported portfolio weights, share counts, and quarter-over-quarter portfolio changes in a structured format. The filing represents a point-in-time snapshot of disclosed long-side exposure, not a real-time or complete view of the fund’s total book.

How do you measure conviction in Vestal Point Capital's portfolio allocations?

Conviction is measured by portfolio weight, the percentage of Vestal Point Capital’s total reported 13F market value allocated to a given position, rather than by absolute share count or dollar value alone. A position representing a disproportionately large share of the fund’s disclosed book signals high-conviction allocation, regardless of whether it ranks among the fund’s largest absolute holdings.

What is excluded from Vestal Point Capital's 13F: short positions, swaps, and derivatives?

SEC Form 13F requires disclosure of long positions only. Specifically excluded are: short interest, total return swaps, credit default swaps, and all OTC derivatives, none of which appear in 13F filings regardless of position size. Listed put and call options must be disclosed but are excluded from portfolio weight calculations on this platform so that reported weights reflect direct equity exposure and remain comparable across filers. This means Vestal Point Capital’s 13F represents the reported long book, which may differ materially from its net economic exposure.

When is Vestal Point Capital's 13F data available, and how large is the reporting lag?

Investment managers must submit Form 13F within 45 calendar days of each quarter-end (the T+45 deadline). Pactolio ingests filings directly from SEC EDGAR as they are published, so managers who file early appear in our system before the deadline, while late filers are captured on their actual filing date. The quarter label shown at the top of this page reflects the most recently processed 13F cycle for Vestal Point Capital. The inherent reporting lag means the data always reflects positions as of the prior quarter-end, not current holdings.

Who must file a Form 13F with the SEC, and does Vestal Point Capital qualify?

Under SEC Rule 13f-1, any investment manager (including hedge funds, family offices, registered investment advisers, pension funds, and university endowments) that exercises investment discretion over $100 million or more in Section 13(f) securities at any point during a calendar year must file Form 13F for that year. Vestal Point Capital meets this threshold, which is why its holdings are publicly disclosed and accessible on this platform. The $100 million threshold is evaluated on a rolling basis, meaning new filers can enter and existing filers can exit the disclosure regime as AUM crosses that boundary.